Nicardipine
From Wikipedia, the free encyclopedia
 |
|
|
Nicardipine
|
|
| Systematic (IUPAC) name | |
| methyl2-(benzyl-methyl-amino)ethyl2,6-dimethyl-4- (3-nitrophenyl)-1,4-dihydropyridine- 3,5-dicarboxylate | |
| Identifiers | |
| CAS number | |
| ATC code | C08 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C26H29N3O6 |
| Mol. mass | 479.525 g/mol |
| Physical data | |
| Melt. point | 6 °C (43 °F) |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | >95% |
| Metabolism | ? |
| Half life | 8.6 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Nicardipine hydrochloride (Cardene) is a medication used to treat high blood pressure and angina. It belongs to the class of calcium channel blockers.
Nicardipine is a dihydropyridine calcium-channel blocking agent used for the treatment of vascular disorders such as chronic stable angina, hypertension, and Raynaud's phenomenon. It is available in oral and intravenous formulations. Its mechanism of action and clinical effects closely resemble those of nifedipine and the other dihydropyridines (amlodipine, felodipine), except that nicardipine is more selective for cerebral and coronary blood vessels. Furthermore, nicardipine does not intrinsically decrease myocardial contractility and may be useful in the management of congestive heart failure. Nicardipine also has a longer half-life than nifedipine. Nicardipine was approved by the FDA in December 1988. The patent for both Cardene and Cardene SR expired in October 1995.
|
|||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
